Abstract
Product description
The present Competitive Intelligence Report about EGF-R agonists and
antagonists provides a competitor evaluation in the field of epidermal growth
factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or
treatment of cancer as of September 2009. Purchase of the downloadable pdf
report includes a 6-month online access to the data of the report and any
updates since the publication date. Credentials to access the database will be
sent by e-mail and allow online work with the project data to print or export
an individual report.
The human epidermal growth factor receptor (HER) family members include EGFR
(erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are
structurally related, and all except HER3 contain intracellular tyrosine
kinase (tk) domain. All of the HER members, except HER2, bind to extracellular
ligands
EGFR, a valid target in many epithelial malignancies, is a transmembrane
protein with an extracellular ligand binding domain joined to an intracellular
tyrosine kinase domain. Activation of EGFR induces a cascade of downstream
signaling through several pathways, such as mitogenac tivated protein kinase
(MAPK) and PI3-kinase / Akt/mTOR, resulting in cellular proliferation,
differentiation, survival, motility, adhesion, and repair. EGFR is
overexpressed or abnormally activated in several epithelial malignancies.
Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R
tyrosine kinase have been approved and are used for treatment of colorectal
cancer, squamous cell cancer of the head & neck or pancreatic cancer,
respectively. EGF-R targeting therapeutics achieved 2008 sales of US$ 3.35 bln.
The pipeline of novel EGF-R targeting molecules is rather full and includes
novel antibody as well as vaccine approaches and small molecules with a
broader inhibition profile. At least six next generation antibodies against
EGF-R are already in clinical development and more than ten biologics are
preclinical R&D including dual target antibodies or vaccines. The small
molecule pipeline is focused on dual EGF-R and Her2 as well as pan-Her tk
inhibitors, but also includes multi-target EGF-R tk inhibitors.
The report includes a compilation of current active projects in research and
development of molecules targeting the EGF receptor. In addition, the report
lists company-specific R&D pipelines of EGF-R targeting small molecules,
antibodies, proteins, cells and vaccines. Competitor projects are listed in a
tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- 2008 Sales of EGF-R Antagonists
- EGF-R Agonists
- Erbitux Pipeline
- Biologics as EGF-R Antagonists
- Selective EGF Receptor Antagonists
- Dual EGF-R and Her2 Receptor Antagonists
- Pan-ErbB (pan-Her) Receptor Antagonists
- Multi-Target EGF-R Antagonists
- Corporate EGF-R Agonist and Antagonist R&D Pipelines
- About La Merie
| 
View Cart
